GeronGERN -3.65%39 PB Ratio is 3.70 as of Jun. 27, 2026, which is 16% above its 10-year median of 3.20. GuruFocus rates GERN with a GF Score™ of 39/100 and a GF Value™ of $6.73 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,232 Biotechnology companies, Geron ranks worse than 62.42% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-27), Geron's share price is $1.32. Geron's Book Value per Share for the quarter that ended in Mar. 2026 was $0.36. Hence, Geron's PB Ratio of today is 3.70.
The historical rank and industry rank for Geron's PB Ratio or its related term are showing as below:
GERN'
s PB Ratio Range Over the Past 10 Years
Min: 1 Med: 3.2 Max: 16.29
Current: 3.7
During the past 13 years, Geron's highest PB Ratio was 16.29. The lowest was 1.00. And the median was 3.20.
GERN's PB Ratio is ranked worse than 62.42% of 1232
companies
in the Biotechnology industry
Industry Median: 2.8
vs GERN: 3.70
During the past 12 months, Geron's average Book Value Per Share Growth Rate was -15.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 19.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -5.50% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -9.80% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Geron was 31.20% per year. The lowest was -33.80% per year. And the median was -4.20% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Geron PB Ratio Related Terms
Geron PB Ratio Historical Data
* Premium members only.
The historical data trend for Geron's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Geron's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Geron PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Geron's PB Ratio distribution charts can be found below:
* The bar in red indicates where Geron's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Geron's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Geron (GERN) has a PB Ratio of 3.70 as of Jun. 27, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Geron and its competitors. This is 16% above median its historical median of 3.20. Over the past decade, Geron's PB Ratio has ranged from 1.00 to 16.29. According to the industry distribution chart, Geron ranks #769 out of 1232 companies in the Biotechnology industry, placing it in the top 62.4%.
Is Geron's PB Ratio too high?
Geron's current PB Ratio of 3.70 is 16% above median its 10-year median of 3.20. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 16.29. The Biotechnology industry median PB Ratio is 2.80. Geron's value of 3.70 is 32.1% above this industry median. Based on the distribution chart, Geron ranks #769 out of 1232 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Geron has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Geron's PB Ratio compare to LBRX and ODTX?
According to the Biotechnology industry distribution chart, Geron ranks #769 out of 1232 companies for PB Ratio. This places Geron in the lower half of its industry. The industry median PB Ratio is 2.80. Geron's value of 3.70 is 32.1% above this benchmark. Historically, Geron's own PB Ratio has ranged from 1.00 to 16.29 over the past decade. While the company's 10-year median is 3.20 vs. the industry median of 2.80, Geron has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Geron's current PB Ratio of 3.70 is 32.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Geron and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Geron's current PB Ratio is 3.70, which is 16% above median its own 10-year median of 3.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Geron stock overvalued right now?
Based on GuruFocus' analysis, Geron (GERN) is currently considered Possible Value Trap. The stock's GF Value™ is $6.73, compared to a current price of $1.32 — trading 80.4% below its estimated fair value. The current PB Ratio is 3.70, which is 16% above median its 10-year median of 3.20 and 32.1% above the Biotechnology industry median of 2.80. Geron's overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Geron (GERN), the current PB Ratio is 3.70 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Geron (GERN) Overvalued in 2026?
Based on GuruFocus' analysis, Geron stock appears to be undervalued.
The current stock price of $1.32 is trading 80.4% below its estimated GF Value™ of $6.73.
GuruFocus considers Geron to be Possible Value Trap.
Key valuation signals for GERN:
PB Ratio: 3.70 (16% above median its 10-year median of 3.20)
GF Value™: $6.73 vs. price of $1.32 (80.4% below fair value)
Industry Position: 32.1% above the Biotechnology median (#769 of 1232)
No single metric tells the full story. See the GERN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
39GF Score
Get the complete analysis for GERN
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GERN has been successfully added to your 
